Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07232641 · ClinicalTrials.gov registry record
Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic
A clinical trial, sponsored by Boston University.
- Recruiting
- Registry status
- 185,810
- Enrollment target
NCT07232641 is a clinical trial that is actively recruiting participants, run by Boston University. The registered enrollment target is 185,810 participants.
The verdict
NCT07232641 is actively recruiting participants, sponsored by Boston University.
- RECRUITING
- Registry status
- 185,810 participants
- Enrollment target
Study Summary
"Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulations than medications for other substance use disorders, including medication for alcohol use disorder (MAUD), which created barriers to MOUD initiation and retention. These barriers were exacerbated by physical distancing and diminished clinic capacities during the COVID-19 pandemic. To prevent healthcare disruption and expand access to MOUD treatment during the public health emergency, federal and state authorities implemented several MOUD policy changes during the pandemic to reduce barriers to MOUD initiation and retention, which subsequently became permanent. This study is an evaluation of the impacts of these policies on treatment use, retention, and patient outcomes pre- and post-MOUD policy implementation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185,810 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2029-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07232641
The ClinicalTrials.gov registry entry for NCT07232641 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 185,810 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07232641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07232641 about?
NCT07232641 is a clinical study titled "Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic". "Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulation...
What is the current status of trial NCT07232641?
This trial is currently recruiting. The enrollment target is 185,810 participants. The study started on 2026-06-30. Estimated completion is 2029-09.
Who is sponsoring clinical trial NCT07232641?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.